Online citations, reference lists, and bibliographies.
Please confirm you are human
(Sign Up for free to never see this)
← Back to Search

Factors Affecting The In Vitro Release Of Recombinant Human Interferon‐γ (rhIFN‐γ) From PLGA Microspheres

J. Yang, J. Cleland
Published 1997 · Chemistry

Save to my Library
Download PDF
Analyze on Scholarcy
A long-acting depot formulation of recombinant human interferon-γ (rhIFN-γ) was achieved by microencapsulation of rhIFN-γ in polylactic-coglycolic acid (PLGA) microspheres by a water-in-oil-in-water technique. The release of protein was assessed with different release devices and buffer systems. The quality of the released protein was quantitated by sodium dodecyl sulfate-size exclusion chromatography, ELISA, and bioactivity assays. The microencapsulation process resulted in an encapsulation efficiency of 100% and the initial release of bioactive, native protein with no subsequent release. Further investigation suggested that the protein did not bind to the PLGA, but a constant and small amount of protein adsorbed to the filter device used for the release studies. The composition of the release media (pH, buffer species, salt concentration, ionic strength, and type and concentration of surfactants) had a profound effect on the in vitro release rate. The effect was mainly due to the differential solubility, stability, and aggregation of rhIFN-γ in the various systems for protein inside the microspheres or released into the bulk solution. The quality of the protein released from the microspheres was also affected by the buffer media upon storage at 5 °C, which, in turn, affected the quantification of released protein. The bicinchoninic acid method typically used to quantitate protein release underestimated protein release because of aggregation. Protein released after several days was less active than the starting material and had lost activity as a result of the inherent instability of rhIFN-γ at 37 °C. The release device, buffer species, pH, and excipients must be assessed in release studies of proteins from polymer matrices because the protein stability and release is dependent on these variables. These studies also indicated that rhIFN-γ was encapsulated and released from PLGA in a bioactive form, but its stability at 37 °C, which was greatly affected by the release conditions, limits the duration of release of native, bioactive protein to 7 days or less.
This paper references
Degradation of poly(lactic-co-glycolic acid) microspheres: effect of copolymer composition.
T. Park (1995)
Development of a single-shot subunit vaccine for HIV-1.
J. Cleland (1994)
Gamma-interferon inhibits extracellular matrix synthesis and remodeling in collagen lattice cultures of normal and scleroderma skin fibroblasts.
P. Gillery (1992)
Long-acting delivery system of interferon: IFN minipellet
K. Fujioka (1995)
Recombinant human growth hormone poly(lactic-co-glycolic acid) (PLGA) microspheres provide a long lasting effect
J. Cleland (1997)
Interferon-α and interferon-γ reduce excessive collagen synthesis and procollagen mRNA levels of scleroderma fibroblasts in culture
V. Kähäri (1988)
Structural studies on acid unfolding and refolding of recombinant human interferon gamma.
Y. R. Hsu (1985)
Replacing succinate with glycolate buffer improves the stability of lyophilized interferon-γ
X. Lam (1996)
Novel delivery system for proteins using collagen as a carrier material : The minipellet
K. Fujioka (1995)
pH dependence of the reversible and irreversible thermal denaturation of gamma interferons.
M. Mulkerrin (1989)
Natural human interferon-gamma. Complete amino acid sequence and determination of sites of glycosylation.
E. Rinderknecht (1984)
Modified release of hydrophilic, hydrophobic and peptide agents from ionized amphiphilic gel networks
H. Yu (1995)
Design and production of single-immunization vaccines using polylactide polyglycolide microsphere systems.
J. Cleland (1995)

This paper is referenced by
Stabilization of recombinant human growth hormone against emulsification-induced aggregation by Pluronic surfactants during microencapsulation.
Gang Wei (2007)
Recombinant human growth hormone poly(lactic-co-glycolic acid) microsphere formulation development.
Jones (1997)
Release of tetanus toxoid from adjuvants and PLGA microspheres: how experimental set-up and surface adsorption fool the pattern.
P. Johansen (1998)
Sustained release of recombinant human insulin-like growth factor-I for treatment of diabetes.
X. Lam (2000)
From natural bone grafts to tissue engineering therapeutics: Brainstorming on pharmaceutical formulative requirements and challenges.
B. Baroli (2009)
Development of a growth factor delivery system
G. T. S. Kirby (2014)
Microspheres as delivery systems for the controlled release of peptides and proteins
V. Sáez (2008)
Polymer degradation and drug delivery in PLGA-based drug-polymer applications: A review of experiments and theories.
Y. Xu (2017)
Sustained interferon-γ delivery from a photocrosslinked biodegradable elastomer
F. Gu (2005)
Developments in Nanoparticle Embedded Biodegradable Polymers for Packaging and Storage of Fruits and Vegetables
R. Gautam (2015)
Enhanced Immunogenicity and Protective Efficacy with the Use of Interleukin-12-Encapsulated Microspheres plus AS01B in Tuberculosis Subunit Vaccination
Sang-Jun Ha (2006)
Principles of encapsulating hydrophobic drugs in PLA/PLGA microparticles.
C. Wischke (2008)
Development of stable formulations for PLGA/PLA microsphere vaccines
J. Cleland (1998)
Novel processing of bioglass ceramics from silicone resins containing micro- and nano-sized oxide particle fillers.
L. Fiocco (2014)
Interferon‐γ therapy: Evaluation of routes of administration and delivery systems
H. Younes (2002)
Temporally regulated delivery of VEGF in vitro and in vivo.
Alessandra B. Ennett (2006)
Endogenous carriers and ligands in non-immunogenic site-specific drug delivery.
S. Vyas (2000)
Polyelectrolyte complex of chondroitin sulfate and peptide with lower pI value in poly(lactide-co-glycolide) microsphere for stability and controlled release.
W. Park (2009)
Sustained release microspheres of metoclopramide using poly(D,L-lactide-co-glycolide) copolymers.
S. Elkheshen (2000)
Bupivacaine-loaded biodegradable poly(lactic-co-glycolic) acid microspheres I. Optimization of the drug incorporation into the polymer matrix and modelling of drug release.
H. Zhang (2008)
Influence of protein content on the physicochemistry of poly(ε-caprolactone) microparticles
B. Youan (2006)
Pharmaceutical and immunological evaluation of a single-shot hepatitis B vaccine formulated with PLGA microspheres.
L. Shi (2002)
Exploiting receptor biology for oral vaccination with biodegradable particulates.
N. Foster (2005)
Stability Assessment and Formulation Characterization
A. Chow (2010)
Hydrophilic biodegradable microspheres of interferon-alpha and its pharmacokinetics in mice.
C. Zheng (2008)
How to achieve sustained and complete protein release from PLGA-based microparticles?
A. Giteau (2008)
Cytokine-Encapsulated Biodegradable Microspheres for Immune Therapy
N. Egilmez (2020)
Controlled and Extended Release of a Model Protein from a Microsphere-Hydrogel Drug Delivery System
Christian Osswald (2015)
Proteins As Microencapsulating Agents And Microencapsulated Active Compounds In
A. Radwick (2002)
Sustained release of insulin-like growth factor-1 from poly(lactide-co-glycolide) microspheres improves osseointegration of dental implants in type 2 diabetic rats.
F. Wang (2010)
Degradable polymer microspheres for controlled drug delivery
U. Edlund (2002)
Thiolated Polymers: Pharmaceutical Tool in Nasal Drug Delivery of Proteins and Peptides
Ashish Jain (2018)
See more
Semantic Scholar Logo Some data provided by SemanticScholar